RhumbLine Advisers’s Chembio diagnostics, Inc. CEMI Stock Holding History

RhumbLine Advisers’s Portfolio CEMI Stock Details CEMI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-17,866	Closed	-$63K	–	3221
2021 Q1	$63K	Hold	17,866	–	–	﹤0.01%	2968
2020 Q4	$85K	Buy	17,866 +1,653	+10%	+$8.54K	﹤0.01%	2982
2020 Q3	$79K	Sell	16,213 -5,990	-27%	-$28.4K	﹤0.01%	2911
2020 Q2	$72K	Buy	+22,203	New	+$211K	﹤0.01%	3004

Other funds holding CEMI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TEE

Tibra Equities Europe London, United Kingdom $90.4M AUM 37.81% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

RhumbLine Advisers's CEMI Position: Q2 2021 in Review

RhumbLine Advisers sold out of Chembio diagnostics, Inc. (CEMI) in Q2 2021, closing a stake of 17,866 shares — an estimated $63K sold.

RhumbLine Advisers first reported a position in CEMI in Q2 2020 and held it in 4 quarters. The position peaked at $85K in Q4 2020. 60 funds tracked by Wall St. Rank hold CEMI as of Q2 2021.

RhumbLine Advisers reported no remaining Chembio diagnostics, Inc. position as of Q2 2021 after selling out during the quarter.
RhumbLine Advisers sold 17,866 Chembio diagnostics, Inc. shares in Q2 2021, an estimated $63K.
RhumbLine Advisers first reported a position in Chembio diagnostics, Inc. in Q2 2020 and held it in 4 quarters.
RhumbLine Advisers's Chembio diagnostics, Inc. position peaked at $85K in Q4 2020.
60 funds tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q2 2021.

Based on RhumbLine Advisers's 13F filing for Q2 2021, filed 5 Aug 2021.